Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sareum Holdings ( (GB:SAR) ) has issued an announcement.
Sareum Holdings has discontinued its 16-week GLP preclinical toxicology study for SDC-1801 due to safety findings observed in control-group animals, which were given an inactive dosing solution. The company is investigating the cause of these findings and plans to restart the study with a new provider, aiming to complete it with existing cash resources. Despite this setback, previous Phase 1 trials showed no safety concerns, and Sareum remains focused on advancing to Phase 2 clinical development for psoriasis.
Spark’s Take on GB:SAR Stock
According to Spark, TipRanks’ AI Analyst, GB:SAR is a Neutral.
Sareum Holdings faces critical financial challenges with zero revenue and ongoing losses, heavily impacting its overall score. Despite these issues, recent strategic advancements and positive corporate events provide some optimism. Technical indicators suggest short-term strength, but valuation remains a concern due to negative earnings.
To see Spark’s full report on GB:SAR stock, click here.
More about Sareum Holdings
Sareum Holdings PLC is a clinical-stage biotechnology company based in Cambridge, UK, specializing in the development of next-generation kinase inhibitors for autoimmune diseases and cancer.
Average Trading Volume: 356,838
Technical Sentiment Signal: Sell
Current Market Cap: £31.75M
See more insights into SAR stock on TipRanks’ Stock Analysis page.